MedTrace Logo

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

NCT00134186 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2007-03-05

No results posted yet for this study

Summary

The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

Conditions

  • Carcinoma, Renal Cell
  • Urogenital Neoplasms
  • Urologic Neoplasms
  • Kidney Neoplasms

Interventions

DRUG

motexafin gadolinium

Sponsors & Collaborators

  • Pharmacyclics LLC.

    lead INDUSTRY

Principal Investigators

  • Robert J Amato, D.O. · Methodist Hospital Genitourinary Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00134186 on ClinicalTrials.gov